MRI comes of age in RA clinical trials

Annals of the Rheumatic Diseases

Volumn 72, Issue 6, 2013, Pages 794-796

  Peterfy, Charles ^a   Østergaard, Mikkel ^b   Conaghan, Philip G ^c  

^a Spire Sciences LLC   (United States)

^b Mental Health Services CPH   (Denmark)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; DENOSUMAB; FOSTAMATINIB; GOLIMUMAB; METHOTREXATE; PLACEBO; RITUXIMAB; TOCILIZUMAB;

BONE EROSION; CHONDROPATHY; CLINICAL TRIAL (TOPIC); DIGITAL RADIOGRAPHY; DRUG EFFICACY; DRUG USE; HUMAN; IMAGE ANALYSIS; JOINT INJURY; JOINT RADIOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SYNOVITIS;

DISEASE ACTIVITY; MAGNETIC RESONANCE IMAGING; RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; HUMANS; MAGNETIC RESONANCE IMAGING; OSTEITIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; SYNOVITIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84877605314     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202696     Document Type: Review

References (28)

1. American College of Rheumatology Rheumatoid Arthritis Clinical Trial Investigators Ad Hoc Task Force. American College of Rheumatology Clinical Trial Priorities and Design Conference, July 22-23, 2010. Arthritis Rheum. 2011;63:2151-6.
2. Seigel EL, Kolodner RM, eds. Filmless radiology. New York, NY: Springer-Verlag, 1999: 137-54.
3. Peterfy C. Outcome measures in rheumatoid arthritis clinical research. 4th Annual meeting, International Society for Musculoskeletal Imaging in Rheumatology 2011. http://www.rheumatologybpi.com (accessed 14 Jan 2013).
4. Dohn UM, Ejbjerg BJ, Court-Payen M, et al. Are bone erosions detected by magnetic resonance imaging and ultrasonography true erosions? A comparison with computed tomography in rheumatoid arthritis metacarpophalangeal joints. Arthritis Res Ther 2006;8:R110.
5. Dohn UM, Ejbjerg BJ, Hasselquist M, et al. Rheumatoid arthritis bone erosion volumes on CT and MRI: reliability and correlations with erosion scores on CT, MRI and radiography. Ann Rheum Dis 2007;66:1388-92. (Pubitemid 47492488)
6. Dohn UM, Ejbjerg BJ, Hasselquist M, et al. Detection of bone erosions in rheumatoid arthritis wrist joints with magnetic resonance imaging, computed tomography and radiography. Arthritis Res Ther 2008;10:R25.
7. Dohn UM, Ejbjerg B, Boonen A, et al. No overall progression and occasional repair of erosions despite persistent in flammation in adalimumab-treated rheumatoid arthritis patients: results from a longitudinal comparative MRI, ultrasonography, CT and radiography study. Ann Rheum Dis 2011;70:252-8.
8. Peterfy CG, Dicarlo JC, Olech E, et al. Evaluating joint-space narrowing and cartilage loss in rheumatoid arthritis using MRI. Arthritis Res Ther 2012;14:R131.
9. McQueen F, Clarke A, McHaffie A, et al. Assessment of cartilage loss at the wrist in rheumatoid arthritis using a new MRI scoring system. Ann Rheum Dis 2010;69:1971-5.
10. Ostergaard M, Boyesen P, Eshed I, et al. Development and preliminary validation of a magnetic resonance imaging joint space narrowing score for use in rheumatoid arthritis: potential adjunct to the OMERACT RA MRI scoring system. J Rheumatol 2011;38:2045-50.
11. Hetland ML, Ejbjerg B, Horslev-Petersen K, et al. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA). Ann Rheum Dis 2009; 68:384-90.
12. Hetland ML, Stengaard-Pedersen K, Junker P, et al. Radiographic progression and remission rates in early rheumatoid arthritis-MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial. Ann Rheum Dis 2010;69 :1789-95.
13. Haavardsholm EA, Boyesen P, Ostergaard M, et al. Magnetic resonance imaging findings in 84 patients with early rheumatoid arthritis: bone marrow oedema predicts erosive progression. Ann Rheum Dis 2008;67:794-800. (Pubitemid 351843277)
14. Jimenez-Boj E, Nobauer-Huhmann I, Hanslik-Schnabel B, et al. Bone erosions and bone marrow edema as defined by magnetic resonance imaging reflect true bone marrow inflammation in rheumatoid arthritis. Arthritis Rheum 2007;56 :1118-24. (Pubitemid 46608636)
15. McQueen FM, Gao A, Ostergaard M, et al. High-grade MRI bone oedema is common within the surgical field in rheumatoid arthritis patients undergoing joint replacement and is associated with osteitis in subchondral bone. Ann Rheum Dis 2007;66:1581-7. (Pubitemid 350205444)
16. Ostendorf B, Peters R, Dann P, et al. Magnetic resonance imaging and miniarthroscopy of metacarpophalangeal joints: sensitive detection of morphologic changes in rheumatoid arthritis. Arthritis Rheum 2001;44:2492-502. (Pubitemid 33049327)
17. Conaghan PG, O'Connor P, McGonagle D, et al. Elucidation of the relationship between synovitis and bone damage: a randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis. Arthritis Rheum 2003;48:64-71. (Pubitemid 36091649)
18. Haavardsholm EA, Ostergaard M, Ejbjerg BJ, et al. Reliability and sensitivity to change of the OMERACT rheumatoid arthritis magnetic resonance imaging score in a multireader, longitudinal setting. Arthritis Rheum 2005;52:3860-7. (Pubitemid 41798224)
19. Haavardsholm EA, Ostergaard M, Ejbjerg BJ, et al. Introduction of a novel magnetic resonance imaging tenosynovitis score for rheumatoid arthritis: reliability in a multireader longitudinal study. Ann Rheum Dis 2007;66 :1216-22.
20. Ostergaard M, Peterfy C, Conaghan P, et al. OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system. J Rheumatol 2003;30:1385-6. (Pubitemid 36666373)
21. Cohen SB, Dore RK, Lane NE, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a 12-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008;58:1299-309. (Pubitemid 351705919)
22. Genovese MC, Kavanaugh A, Weinblatt ME, et al. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum 2011;63:337-45.
23. Peterfy C, Durez P, Haraoui B, et al. Responses to early rheumatoid arthritis (RA) to treatment with adalimumab plus methotrexate vs. Methotrexate alone: magnetic resonance imaging results from OPTIMA. Ann Rheum Dis 2010;69(suppl-3):455.
24. Conaghan PG, Durez P, Alten RE, et al. Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial. Ann Rheum Dis 2012 (epub ahead of print Published Online First: 21 August 2012).
25. Peterfy C, Emery P, Tak PP, et al. Rituximab (RTX) plus methotrexate (MTX) prevents bone erosion and joint-space narrowing (JSN) and reduces synovitis, osteitis as shown on MRI: results from a randomized placebo controlled trial in patient (Pts) with rheumatoid arthritis (RA-SCORE). Ann Rheum Dis 2011; 70(suppl-3):152.
26. Ostergaard M, Emery P, Conaghan PG, et al. Significant improvement in synovitis, osteitis, and bone erosion following golimumab and methotrexate combination therapy as compared with methotrexate alone: a magnetic resonance imaging study of 318 methotrexate-naive rheumatoid arthritis patients. Arthritis Rheum 2011;63:3712-22.
27. Conaghan PG, Emery P, Ostergaard M, et al. Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial. Ann Rheum Dis 2011;70:1968-74.
28. Troum O, Peterfy C, Olech E, et al. Early reductions in synovitis and osteitis with tocilizumab therapy are maintained through week 52: results from the ACT-RAY MRI Substudy. Ann Rheum Dis 2011; 70(suppl):613.